No Negative in Madrigal Pharma's (MDGL) Topline Data Delay - H. C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Pre-Open Stock Movers 12/30: (NAKD) (KR) (TSCO) Higher; (BIIB) (DIDI) (MDGL) Lower (more...)
December 30, 2021 9:29 AM ESTPre-Open Stock Movers:
Biogen (NASDAQ: BIIB) 5.5% LOWER; Samsung Group denied it is engaged in talks to acquire the biotech firm.
Naked Brand Group Limited (NASDAQ: NAKD) 4.7% HIGHER; sees continued momentum.
DiDi Global Inc. (NYSE:... More
Madrigal Pharma (MDGL) Announces Delay in Release of Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom
December 30, 2021 8:01 AM ESTMadrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today provides an update on MAESTRO-NAFLD-1, its 52-week Phase 3 multi-center, double-blind, randomized, placebo-controlled study of resmetirom in patients with non-alcoholic fatty liver disease, presumed NASH.
Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, Although the blinded study data were delivered to the vendor conducting the statistical analyses on time, unexpected staffing issues at the vendor delayed their analyses of the initial MRI-PDFF and lipid data planned for release by year end. We now expect to announce topline 52-week results from the study in January... More
